)
Hetal Marble
CBO,
ImmutoScientific
Hetal Marble is Chief Business Officer at Immuto Scientific, where she leads licensing, business development, marketing, and product strategy for the company’s high-throughput, residue-level protein characterization platform. She supports Immuto’s growth as a CRO for epitope and paratope mapping. Previously, she led commercial growth and product launches across diagnostics, biomarkers, and research tools at Quanterix, Promega, and Pall Biotech. At MGH’s Center for Integrated Diagnostics, she built an in-house CRO focused on precision biomarkers. Hetal holds a Ph.D. from Brown University, is an inventor on two U.S. patents, and remains active in AMP and Women in Bio.
Sessions
-
19-Feb-2025Opening Address & Keynote Presentation: A Structure-Guided Path to Efficacious Antibodies for Precision Therapy
-
19-Feb-2025Stop shooting in the dark: Leveraging early structural insights to power rational antibody lead design & optimization
-
19-Feb-2025Lead Identification & Optimization: Empirical, Solution-State Epitope/Paratope Interactions to Constrain In Silico Models for Antibody Design and Targeted Engineering
-
06-May-2026Spotlight Presentation: Multimodal Fusion of Empirical Structural Data and Deep Learning for Improved Modeling of Antibody–Antigen Complexes